Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,108 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,662 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,158)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00180895 | Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL | terminated | Phase 2 | 40 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 11, 2006 | clinicaltrials |
| NCT00355212 | Comparison Between Radiofrequency Versus Ethanol Injection for the Treatment of Hepatocellular Carcinoma | terminated | Phase 3 | 240 | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | Jul 25, 2006 |
| NCT00337506 | Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | terminated | Phase 2 | 50 | Nantes University HospitalOTHER | 1 | Jun 16, 2006 | clinicaltrials |
| NCT00114946 | A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer | terminated | Phase 4 | 800 | Genentech, Inc.INDUSTRY | 0 | May 29, 2006 | clinicaltrials |
| NCT00209703 | Feasibility Study of mFOLFOX6 in Patients With Advanced Colorectal Cancer | terminated | Phase 2 | 30 | Hokkaido Gastrointestinal Cancer Study GroupOTHER | 1 | Apr 21, 2006 | clinicaltrials |
| NCT00179725 | Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | terminated | Phase 1 / Phase 2 | 60 | Celgene CorporationINDUSTRY | 1 | Apr 12, 2006 | clinicaltrials |
| NCT00303407 | Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative Care | terminated | — | — | University Hospital, GenevaOTHER | 1 | Mar 16, 2006 | clinicaltrials |
| NCT00101621 | Pilot Study to Evaluate the Safety and Analgesic Activity of M40403 Co-Administered With an Opioid Agent for Cancer Pain | terminated | Phase 2 | 24 | MetaPhore PharmaceuticalsINDUSTRY | 0 | Feb 9, 2006 | clinicaltrials |
| NCT00100737 | Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL) | terminated | Phase 2 | 300 | Chiron CorporationINDUSTRY | 1 | Feb 6, 2006 | clinicaltrials |
| NCT00103428 | Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 69 | Cell GenesysINDUSTRY | 1 | Feb 2, 2006 | clinicaltrials |
| NCT00151645 | Efficacy of Activated Lymphocytes in Renal Cell Carcinoma. | terminated | Phase 2 | 36 | Rennes University HospitalOTHER | 1 | Jan 2, 2006 | clinicaltrials |
| NCT00219765 | Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients | terminated | Phase 1 / Phase 2 | 30 | Poitiers University HospitalOTHER | 1 | Nov 28, 2005 | clinicaltrials |
| NCT00179738 | A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer. | terminated | Phase 2 | 40 | Celgene CorporationINDUSTRY | 1 | Nov 23, 2005 | clinicaltrials |
| NCT00179751 | A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas | terminated | Phase 1 / Phase 2 | 50 | Celgene CorporationINDUSTRY | 1 | Nov 7, 2005 | clinicaltrials |
| NCT00189371 | Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum | terminated | Phase 3 | 300 | AGO Study GroupOTHER | 1 | Sep 19, 2005 | clinicaltrials |
| NCT00162695 | Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood | terminated | Phase 3 | 400 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 13, 2005 | clinicaltrials |
| NCT00083473 | A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia | terminated | Phase 2 | 28 | Titan PharmaceuticalsINDUSTRY | 1 | Aug 30, 2005 | clinicaltrials |
| NCT00087477 | A Pilot Study of Pivanex in Patients With Malignant Melanoma | terminated | Phase 1 / Phase 2 | 14 | Titan PharmaceuticalsINDUSTRY | 1 | Aug 30, 2005 | clinicaltrials |
| NCT00127595 | Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract | terminated | Phase 2 | 28 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 24, 2005 | clinicaltrials |
| NCT00126243 | Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's Lymphoma | terminated | Phase 2 | 60 | French National Agency for Research on AIDS and Viral HepatitisOTHER_GOV | 1 | Aug 17, 2005 | clinicaltrials |
| NCT00023166 | Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas | terminated | Phase 1 | — | Enzon Pharmaceuticals, Inc.INDUSTRY | 0 | Jun 24, 2005 | clinicaltrials |
| NCT00034333 | Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer | terminated | Phase 2 / Phase 3 | 240 | FeRxINDUSTRY | 8 | Jun 24, 2005 | clinicaltrials |
| NCT00043459 | Study of T900607-Sodium in Previously Treated Patients With Non-Hodgkin's Lymphoma. | terminated | Phase 2 | 35 | TularikINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00057382 | T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients | terminated | Phase 2 / Phase 3 | 750 | TularikINDUSTRY | 11 | Jun 24, 2005 | clinicaltrials |
| NCT00064636 | Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors | terminated | Phase 1 | 46 | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | Jun 24, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Sep 11, 2006source: clinicaltrials